Nant Capital, the investment vehicle of Dr. Patrick Soon-Shiong, focuses on leveraging technology across healthcare, commerce, and entertainment sectors. Operating primarily in the United States, the firm invests in various stages including Series A, B, C, post-IPO debt, and equity rounds. Nant Capital typically engages in substantial investments, with portfolio companies raising amounts ranging from $5 million to over $600 million.
Notable portfolio companies include ImmunityBio, Heliogen, and NantHealth. Dr. Patrick Soon-Shiong, renowned for inventing the nanoparticle chemotherapeutic agent Abraxane, leads the firm. Nant Capital's investment philosophy centers on convergence and innovation, aiming to solve global problems through advanced technologies. The firm offers unique value-add services by integrating its investments within the broader ecosystem of NantWorks, enhancing synergies across its diverse portfolio.
Nant Capital - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages